Manchester personalised medicine company, DxS, has signed a collaboration agreement with Bristol-Myers Squibb Company and ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to further develop a K-RAS companion diagnostic for ERBITUX® (cetuximab) in the United States of America and Canada.
If approved by the US Food and Drug Administration, the DxS TheraScreen®: K-RAS Mutation Kit could become a companion diagnostic for use with ERBITUX in metastatic colorectal cancer (mCRC) to determine which patients have wild-type K-RAS status.
Dr Stephen Little, CEO of DxS commented: “We are very pleased to be continuing our work with Bristol-Myers Squibb and ImClone Systems to ensure K-RAS testing is available to all patients in need of treatment for metastatic colorectal cancer in the United States.”
DxS, founded in 2001, provides molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies, DxS will support the development and sales of targeted cancer therapies by providing biomarkers and companion diagnostics.
Ends
To comment please login above.
Bookmark this: